title: [Efficacy and safety of valdoxan in patients with irritable bowel syndrome].
abstract: OBJECTIVE
  To evaluate the efficacy and safety of the antidepressant valdoxan in irritable bowel syndrome (IBS) with comorbid mild and moderate depression.
  
  
  METHODS
  Twenty-eight patients with IBS and depression without psychotic symptoms were studied using clinical examination and psychometric scales.
  
  
  RESULTS
  A significant reduction in psychopathological symptoms, along with the improvement of health status, was recorded for most patients treated with valdoxan (25-50 mg/night) in the end of the 1st week.
  
  
  CONCLUSIONS
  Valdoxan has a good tolerability and safety profile, does not exert any negative effect on the IBS course and provides a high level of compliance.
authors.forename: I V
authors.initials: IV
authors.lastname: Balakina
authors.forename: T Ia
authors.initials: TIa
authors.lastname: Mironova
authors.forename: E N
authors.initials: EN
authors.lastname: Golovanova
mesh_terms: D000081:Acetamides / Q000009:adverse effects / Q000627:therapeutic use*; D000328:Adult; D000928:Antidepressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D003863:Depression / Q000150:complications / Q000188:drug therapy*; D005260:Female; D006801:Humans; D043183:Irritable Bowel Syndrome / Q000150:complications / Q000523:psychology*; D008297:Male; D008875:Middle Aged; D011594:Psychometrics; D009281:Naphthalenes
chemical_list: D000081:Acetamides; D000928:Antidepressive Agents; C084711:agomelatine; D009281:Naphthalenes